An interventional study of Rosiglitazone and Acarbose in Polycystic Ovary Syndrome, sponsored by Jean-Patrice Baillargeon. Completed at 1 site in Canada. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-20.
Sponsored by Jean-Patrice Baillargeon · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Polycystic Ovary Syndrome with a site in Canada — 3 open to participants now, 4 under way, none of them phase 3. Polycystic Ovary Syndrome · Canada.
Among the 16 studies in Polycystic Ovary Syndrome with a site in Canada, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2006, is one of 9 with no phase, and was the 2nd registered.
958 studies on the registry are indexed under Polycystic Ovary Syndrome; 175 are open to participants now.
Browse Polycystic Ovary Syndrome studies →3 of the 16 studies in Polycystic Ovary Syndrome with a site in Canada are open now. Recruiting first, the newest first:
McGill University · Sites in Canada
Ages 18–40 · Healthy volunteers
Quanovate Tech Inc. · Sites in Canada
Ages 18–55 · Women only · Healthy volunteers
Ottawa Hospital Research Institute · Sites in Canada
Ages 18–99 · Women only
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 119 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 105 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 40 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 70 across 699 interventional studies indexed under Polycystic Ovary Syndrome.
Median enrollment 52 across the 12 interventional studies, 75 across the 4 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 16 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Jean-Patrice Baillargeon as lead sponsor.
Jean-Patrice Baillargeon has 1 study filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Polycystic Ovary Syndrome with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05632601Ottawa Heart Institute Research CorporationReexamining Her Cardiovascular Risk - Ottawa WomeN's Longitudinal Cohort Study | 2026-12-31 |
| NCT06155708McGill UniversityExogenous Ketone Supplementation in Females with Polycystic Ovary Syndrome | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Polycystic Ovary Syndrome with a site in Canada, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The investigators hypothesis is that free fatty acids (FFA) accumulation in non fatty tissues would lead to insulin resistance and hyperandrogenism in PCOS women. Accordingly, Peroxisome Proliferator-Activated Receptor gamma (PPARγ) agonist (rosiglitazone) would be a great therapeutic option for PCOS as their activation induces transcription factors of gene implicated in fatty acids metabolism.
The aim is to verify if insulin-related hyperandrogenism can be reversed in women having polycystic ovary syndrome following an 8-week treatment with rosiglitazone compared to simple insulin reduction with acarbose.
For the purpose of this study, 14 lean women (BMI ≤ 25 kg/m2) and 36 obese women (BMI 30-39 kg/m2) with PCOS as well as 14 lean and 14 obese control women will be recruited to determine their insulin sensibility (insulin levels, M-value, metabolic clearance rate of glucose)and FFA metabolism (FFA levels, rythm of apparition and disapearance of FFA) during a 75g oral glucose tolerance test and a 2-step insulin-glucose clamp.
Polycystic ovary syndrome (PCOS) is a very common but complex endocrine disorder affecting 6 to 10% of childbearing age women. To diagnose PCOS, women must display two of these three symptoms: clinical or biochemical hyperandrogenism, oligoamenorrhea, and/or echographycally confirmed polycystic ovary. Many studies have also demonstrated that PCOS women are more insulin resistant than control women when matched for body mass index (BMI). Thus, insulin resistance (IR) and secondary hyperinsulinemia would be important premises in the development of PCOS. In fact, the prevalence of type 2 diabetes (T2D) is tripled in PCOS women.
Higher free fatty acid (FFA) concentrations were also observed in the circulation of PCOS women. As FFA accumulates in liver and muscle instead of fat cells, this could be an important cause of IR according to the theory of lipotoxicity. Some indirect evidences are suggesting that FFA accumulation in androgen secreting cells (ovary and adrenal gland) could enhance their androgen production. Based on these findings, our hypothesis is that FFA accumulation in non fatty tissues would lead to IR and hyperandrogenism in PCOS women. Accordingly, Peroxisome Proliferator-Activated Receptor gamma (PPARγ) agonist (rosiglitazone) would be a great therapeutic option for PCOS as their activation induces transcription factors of gene implicated in fatty acids metabolism.
The aim is to verify if insulin-related hyperandrogenism can be reversed in PCOS women following an 8-week treatment with rosiglitazone compared to simple insulin reduction with acarbose. For the purpose of this study, 14 lean women (BMI ≤ 25 kg/m2) and 36 obese women (BMI 30-39 kg/m2) with PCOS as well as 14 lean and 14 obese control women will be recruited to determine their insulin sensibility (insulin levels, M-value, metabolic clearance rate of glucose)and FFA metabolism (FFA levels, rythm of apparition and disapearance of FFA) during a 75g oral glucose tolerance test and a 2-step insulin-glucose clamp.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
PCOS :
Health volunteers :
Exclusion Criteria:
Healthy volunteers :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lean and obese PCOS women
Drug: Rosiglitazone
Obese PCOS women
Drug: Acarbose
Obese and lean healthy women evaluated only at baseline
4 mg twice daily for 8 weeks orally
Also known as: Avandia
100 mg three times daily for 8 weeks orally
Also known as: Prandase
Androgen hyper-responsiveness to insulin - Ratio
The calculated ratio of free testosterone to the area under the insulin curve during an OGTT
Time frame: 8 weeks
Androgen hyper-responsiveness to insulin - Relationship
Determined by the relationship between testosterone and insulin levels during an OGTT.
Time frame: 8 weeks
Insulin sensitivity
Determined by a 2-step insulin-glucose clamp
Time frame: 8 weeks
Insulin secretion
Determined by a 2-step insulin-glucose clamp
Time frame: 8 weeks
Hepatic glucose production
Determined by a 2-step insulin-glucose clamp
Time frame: 8 weeks
Plasma DCI-IPG during euglycemic-hyperinsulinemic clamp
Measured during steady-state
Time frame: 8 weeks
The record gives a start of Aug 2006, a primary completion of Jul 2021 and a completion of Jul 2021. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rosiglitazone